Exploring the role of circulating glial fibrillary acidic protein and neurofilament light chain in myasthenia gravis Caterina Maria Gambino, Luisa Agnello, Concetta Scazzone, Martina Tamburello, Anna Masucci, Roberta Vassallo, Vincenzo Di Stefano, Filippo Brighina, Marcello Ciaccio Clinica Chimica Acta, 2026 BACKGROUND: Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction caused by antibodies against the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). Although these antibodies enable diagnosis, they correlate poorly with disease activity and prognosis. Emerging data suggest that MG involves broader neuroimmune mechanisms beyond the peripheral synapse. Glial fibrillary acidic protein (GFAP), a marker of astroglial activation, and neurofilament light chain (NfL), a marker of neuroaxonal injury, have been proposed as circulating biomarkers in several neurological diseases. This study aimed to evaluate serum GFAP and NfL concentrations in MG patients and to assess its potential diagnostic utility. METHODS: In this retrospective case-control study, 137 patients with confirmed MG and 338 healthy controls were enrolled. Clinical classification followed MGFA criteria. Anti-AChR and anti-MuSK antibodies were measured by ELISA. Serum GFAP and NfL concentrations were quantified using a fully automated chemiluminescent immunoassay (Lumipulse G1200). Group comparisons were performed using non-parametric tests, correlations using Spearman analysis, and independent determinants assessed with multivariable linear regression. Receiver operating characteristic (ROC) curve analysis was performed to evaluate diagnostic performance. RESULTS: Serum GFAP concentrations were higher in MG patients than controls (44.6 vs 29.6 pg/mL) and strongly correlated with age (r = 0.64, p < 0.0001), but not with antibody titers. In multivariable regression, age was the main independent determinant of GFAP (β = 0.00827, p < 0.0001), whereas MG status was not. GFAP showed moderate diagnostic performance (AUC = 0.704). In an age- and sex-matched analysis, NfL concentrations were modestly higher in MG patients compared with controls (30.2 vs 15.5 pg/mL; p = 0.047). A moderate positive correlation between GFAP and NfL was observed in both groups. CONCLUSIONS: Circulating GFAP levels are elevated in MG but are primarily driven by age and sex rather than disease-specific mechanisms, limiting their diagnostic utility. NfL shows a modest increase, suggesting subtle neuroaxonal involvement; however, its clinical relevance remains uncertain. Together, these findings indicate that GFAP and NfL reflect non-specific neurobiological processes rather than robust biomarkers of MG.
Neurophysiological assessment of disease severity in Friedreich's Ataxia: a study of brainstem auditory and visual evoked potentials Simona Maccora, Umberto Quartetti, Salvatore Maria Lima, Nicasio Rini, Marco Cucchiara, Luisa Agnello, Caterina Maria Gambino, Filippo Brighina, Marcello Ciaccio, Vincenzo Di Stefano Clinical Neurophysiology, 2026 OBJECTIVE: To evaluate a multimodal assessment including clinical rating scales, brainstem auditory evoked potentials (BAEPs), pattern reversal visual evoked potentials (p-VEPs), and serum biomarkers as candidate measures of disease severity in longstanding Friedreich's ataxia (FRDA). METHODS: In a prospective, monocentric cohort, we conducted a cross-sectional baseline assessment of 29 genetically confirmed adult FRDA patients. Disease severity was rated with modified Friedreich Ataxia Rating Scale (mFARS). All underwent BAEPs and/or p-VEPs; available serum markers (NfL, NfH, GFAP, IL-6) were assayed. Associations with mFARS were tested using correlations and multiple linear regression adjusted for age and disease duration. RESULTS: = 0.83), with disease duration (β = 0.62, p = 0.001) and N75 latency (β = 0.45, p = 0.005). Patients with abnormal BAEPs had higher mFARS than those with normal BAEPs (U = 35.0, p = 0.03). mFARS differed across BAEP grades (H(4,N = 28) = 10.22, p = 0.04) and p-VEP grades (H(4,N = 27) = 11.39, p = 0.02). Serum biomarkers showed no consistent association with mFARS. CONCLUSIONS: BAEPs and p-VEPs are highly prevalent and closely associated with clinical severity in chronic FRDA, outperforming tested serum biomarkers. SIGNIFICANCE: Evoked potentials provide accessible, non-invasive, quantitative candidate biomarkers for severity assessment and longitudinal monitoring in FRDA, supporting their use in clinical practice and trial design when fluid markers are inconclusive.
Efgartigimod in Patients with Generalized Myasthenia Gravis Refractory or Intolerant to IVIg Flora D’Amico, Sofia Campo, Nicasio Rini, Claudia Vinciguerra, Liliana Bevilacqua, Carmen Erra, Paolo Barone, Francesco Tuccillo, Francesco Habetswallner, Filippo Brighina, Vincenzo Di Stefano Neurology and Therapy, 2026 INTRODUCTION: Generalized myasthenia gravis (gMG) is a rare chronic autoimmune disorder of the neuromuscular junction caused by pathogenic autoantibodies directed against a postsynaptic target. The therapeutic landscape of gMG has recently expanded with the introduction of FcRn inhibitors. This study aimed to assess the real-world effectiveness and safety of efgartigimod (EFG) in AChR-positive gMG patients who failed or were intolerant to intravenous immunoglobulin (IVIg). METHODS: EFG was administered as four consecutive weekly intravenous infusions at 10 mg/kg. Treatment efficacy was evaluated using the Myasthenia Gravis Activity of Daily Living (MG-ADL) and Myasthenia Gravis quantitative (QMG) scales at baseline and after 4 weeks. Incidence of adverse events and prednisone use were collected at each time point. RESULTS: Thirteen patients (6 women and 7 men, mean age 52.9 years) received EFG following IVIg therapy. After one treatment cycle, both MG-ADL and QMG scores showed significant clinical improvement. MG-ADL responder rate (MG-ADL reduction > 2) was 84.6% while 69.2% on QMG (QMG reduction > 3). Minimal symptom expression was reached in one patient, accompanied by a mean reduction in daily prednisone dose of 6.9 mg. CONCLUSION: In this real-world cohort, efgartigimod demonstrated a rapid and meaningful clinical benefit with a favorable tolerability profile in patients with AChR-positive gMG after IVIg failure or intolerance. These findings support the potential role of EFG as an effective therapeutic option in this difficult-to-treat population.
Deep Phenotyping of F64L Mutation in a Multicentric Cohort of Patisiran-Treated Hereditary Transthyretin Amyloidosis Patients (Patisiranitaly) Marco Ceccanti, Pietro Guaraldi, Angela Romano, Giovanni Antonini, Alessandro Barilaro, Chiara Briani, Marco Burattini, Micol Gianoli, Giulia Carlini, Vittoria Cianci, Marco Currò Dossi, Daniela Di Lisi, Antonio Di Muzio, Adele Ratti, Massimiliano Filosto, Sabrina Gasverde, Chiara Gemelli, Luca Gentile, Mariangela Goglia, Luca Leonardi, Simone Longhi, Antonio Lotti, Fiore Manganelli, Anna Mazzeo, Sofia Maria Augello, Giammarco Milella, Giuseppina Novo, Davide Pareyson, Silvia Fenu, Giovanni Palumbo, Cristina Petrelli, Loris Poli, Luca Guglielmo Pradotto, Massimo Russo, Alessandro Salvalaggio, Maria Ausilia Sciarrone, Luigi Sellitti, Matteo Tagliapietra, Stefano Tozza, Mariagiovanna Castiglia, Mara Turri, Lorenzo Verriello, Cristina Chimenti, Francesca Vitali, Filippo Brighina, Nicasio Rini, Maurizio Inghilleri, Roberto D'Angelo, Domenico Abelardo, Chiara Cambieri, Laura Libonati, Federica Moret, Marco Luigetti, Vincenzo Di Stefano European Journal of Neurology, 2026 Background The F64L variant is among the most frequent TTR mutations in Italy, typically associated with a predominantly neurologic phenotype and limited cardiac involvement. Methods Data from 181 ATTRv patients in the multicenter Patisiranitaly database treated with Patisiran since 2020 were analyzed. Neurologic impairment scores, Norfolk QoL‐DN, and cardiac parameters were compared between F64L ( n = 56), V30M ( n = 37), and non‐F64L ( n = 125) patients at baseline and during follow‐up. Cluster analysis was applied to identify patient subgroups based on these variables. Results F64L represented 30.9% of the cohort. Compared to non‐F64L patients, F64L patients had a higher prevalence of neurologic onset and neurologic phenotype, a thinner interventricular septum, and lower NT‐proBNP levels. Cluster analysis segregated patients into two distinct groups, predominantly reflecting F64L vs. non‐F64L status and corresponding neurologic severity. F64L patients showed milder cardiac involvement compared to V30M patients. Longitudinal repeated‐measures ANOVA showed stable clinical and instrumental measures. Conclusions F64L is characterized by predominant neurologic involvement and milder cardiac involvement in this Patisiran‐treated cohort. Mutation‐specific diagnostic and follow‐up strategies are essential to capture its natural history and treatment response.
The phenotypic spectrum and genetic determinants of severe spinal muscular atrophy in individuals with a single SMN2 copy: an international retrospective observational study Gianpaolo Cicala, Anna Capasso, Marianna Villa, Giorgia Coratti, Chiara Arpaia, Caterina Agosto, Stefania Corti, Federica Ricci, Claudio Bruno, Susan Matesanz, Brianna Gross, Daniel Guillen Mendoza, Nancy Kuntz, Janbernd Kirschner, Andreas Ziegler, Laurent Servais, Fay-Linn Asselman, Ludo van der Pol, Claudia Castiglioni, Andres Nascimiento, Eduardo Fidel Tizzano, Rodrigo Holanda Mendonça, Edmar Zanoteli, Pinki Munot, Mariacristina Scoto, Richard Finkel, Marika Pane, Francesco Danilo Tiziano, Eugenio Mercuri, Antonella Pini, Valeria Sansone, Emilio Albamonte, Giulia Gilberti, Antonio Varone, Ilaria Bitetti, Paolo Alonge, Filippo Brighina, Michele Sacchini, Martina Ricci, Barbara Risi, Noemi Brolatti, Romina Venditti, Maddalena Bianchetti, Roberto De Sanctis, Daniela Leone, Concetta Palermo, Beatrice Berti, Chiara Cutri, Chiara Bravetti, Francesca Magri, Delia Gagliardi, Giacomo Comi, Dario Ronchi Eclinicalmedicine, 2026 Background: copy and the possible association with genotype and outcome. Methods: copy, including clinical severity, genotype, treatment exposure, and survival at last follow-up. Findings: . Interpretation: copy with milder phenotypes carried variants known to mitigate disease severity. Further prospective studies are needed to better define genotype-phenotype correlations and inform treatment decisions in this population. Funding: Some of the data in this study originate from disease registries at least partially funded by Biogen, Novartis and Roche.
Nerve Ultrasound in Pediatric Polyneuropathies: A Systematic Review Simona Maccora, Vincenzo Di Stefano, Filippo Brighina, Sabrina Sacconi, Angela Puma Neuropediatrics, 2026 The diagnosis of peripheral polyneuropathy in children and the differential diagnosis among its various forms often present a challenge, also because electrodiagnostic studies can be painful and sometimes yield inconclusive results. This systematic review examines the role of nerve ultrasound (n-US) in the diagnosis and follow-up of pediatric polyneuropathies. We searched PubMed and Embase from 1975 to April 1, 2025. Included studies assessed patients aged ≤ 18 years with clinically and neurophysiologically confirmed polyneuropathy, providing pediatric-specific qualitative or quantitative n-US findings. Eighteen studies met the inclusion criteria. Six focused on acquired inflammatory polyneuropathies (three on Guillain–Barré Syndrome [GBS], three on Chronic Inflammatory Demyelinating Polyneuropathy [CIDP]), eight on Charcot–Marie–Tooth disease (CMT), two on lysosomal storage disorders, one on Autosomal Recessive Spastic Ataxia of Charlevoix–Saguenay (ARSACS), and one on mixed etiologies. Most (n = 7) were case reports. Cross-sectional area and nerve enlargement (NE) distribution were the main parameters evaluated. Marked, diffuse NE was found in demyelinating CMT and lysosomal disorders; CIDP showed diffuse and multifocal NE; GBS presented mild and proximal NE. No NE was reported in axonal CMT or ARSACS. Few studies assessed echogenicity or fascicular structure; none evaluated vascularization. n-US shows promise in differentiating demyelinating conditions such as CMT, CIDP, GBS, and certain metabolic syndromes in children. However, further age-matched control studies are needed, given that nerve growth and myelination peak between 15 and 17 years. Future research should explore n-US as an early diagnostic, screening, and follow-up tool.
Telecoaching Interventions for People with Epilepsy: Enhancing Physical Activity and Quality of Life through Digital Health. A Systematic Review Ignazio Leale, Fabio Tiziano Orlando, Vincenzo Di Stefano, Salvatore Maria Lima, Manuel Gómez-López, Filippo Brighina, Giuseppe Battaglia Epilepsy and Behavior, 2026 People with Epilepsy exhibit low levels of physical activity compared with the general population, despite evidence suggesting potential benefits for seizure control, physical fitness and psychosocial well-being. Persistent barriers such as fear of seizures, limited access to supervised programs, transportation difficulties, and time constraints contribute to sedentary behaviour. Telecoaching (TC), which delivers structured exercise programs through digital technologies, may help overcome these barriers. This systematic review aimed to evaluate the feasibility and potential effects of TC-based training physical activity interventions in individuals with epilepsy, focusing on adherence, QoL, physical fitness and psychological outcomes. A systematic search of PubMed, Web of Science, and Scopus identified 1086 records, of which 7 studies involving 342 participants met the inclusion criteria. Interventions included remotely delivered aerobic, resistance, flexibility, and combined exercise programs. Study quality ranged from "fair" to "good". TC-based interventions were generally safe and feasible, with no major adverse events reported. Evidence suggest potential benefits for physical fitness and psychosocial outcomes, particularly in paediatric populations, although the limited number and heterogeneity of studies preclude definitive conclusions, especially regarding seizure-related outcomes. Future research should focus on standardized TC programs, long-term follow-up, and adequately powered randomized trials to confirm effectiveness and sustainability.
Physical Exercise in Myasthenia Gravis: A Systematic Review Claudia Vinciguerra, Ignazio Leale, Nicasio Rini, Fabio Tiziano Orlando, Liliana Bevilacqua, Paolo Barone, Filippo Brighina, Vincenzo Di Stefano, Giuseppe Battaglia Healthcare Switzerland, 2026 Background: Myasthenia gravis (MG) is a chronic autoimmune disorder characterized by fluctuating skeletal muscle weakness and fatigue, leading to reduced functional independence and impaired quality of life (QoL). Although exercise has historically been discouraged due to concerns about symptom exacerbation, emerging evidence suggest that structured exercise programs may be safe and beneficial in clinically stable patients. This systematic review critically evaluates current evidence on exercise and physical activity interventions in MG, focusing on effectiveness, safety, and impact on functional outcomes, fatigue, and QoL. Materials and Methods: A systematic review was conducted following PRISMA guidelines. Searches were performed in PubMed, Web of Science, Google Scholar, Scopus and ScienceDirect for studies published between 2015 and 2025. Keywords included MG, physical activity, aerobic training, resistance training, and respiratory muscle training. Methodological quality was assessed using the Downs and Black checklist. Results: Eight controlled studies met the inclusion criteria, encompassing aerobic, resistance, combined, and respiratory muscle training interventions. Sample sizes ranged from small pilot studies to moderate-size randomized controlled trials. Overall, exercise interventions were well tolerated, with no evidence of sustained symptoms exacerbation. Aerobic and combined programs consistently improved functional capacity, muscle strength, and activities of daily living. Respiratory muscle training demonstrated improvements in pulmonary function and inspiratory muscle strength, although findings were more heterogeneous. Study quality ranged from poor to excellent, with common limitations including small sample size, short follow-up duration, and heterogeneity in exercise programs. Conclusions: Current evidence supports the safety and potential efficacy of individualized, symptom-guided exercise interventions in clinically stable MG. Regular physical activity exercise may reduce secondary deconditioning, improve functional outcomes, and enhance QoL. However, larger, high-quality randomized controlled trials with standardized programs and longer follow-up periods are required to strengthen clinical recommendations and clarify long-term effects.
Evaluating effects of risdiplam in adults with spinal muscular atrophy: a monocentric study Grazia Crescimanno, Paolo Alonge, Antonino Lupica, Vito Tomasello, Vincenzo Di Stefano, Filippo Brighina, Oreste Marrone Erj Open Research, 2026 <title>Extract</title> Spinal muscular atrophy (SMA) is a rare, autosomal recessive neuromuscular disorder caused by reduced survival motor neuron (SMN) protein due to mutations in the SMN1 gene [1]. In humans, this protein is also produced by a “backup” gene, SMN2. Two drugs, nusinersen and risdiplam, are available, which lead to the production of more full-length, functional SMN protein from the SMN2 gene [2].
Psychopathology in myasthenia gravis: Results from a multicenter Italian study Claudia Vinciguerra, Giuseppe Montalbano, Valentina Virzì, Nicasio Rini, Christian Messina, Liliana Bevilacqua, Paolo Barone, Maria D’Apolito, Eliana Liberatoscioli, Antonio Di Muzio, Roberto Monastero, Filippo Brighina, Vincenzo Di Stefano Journal of Neuroimmunology, 2026
Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study Vincenzo Di Stefano, Nicasio Rini, Carlo Antozzi, Paolo Emilio Alboini, Paolo Alonge, Liliana Bevilacqua, Fiammetta Biasini, Alvino Bisecco, Silvia Bonanno, Filippo Brighina, Luca Codeluppi, Giulia D'Alvano, Valentina Damato, Carmen Erra, Laura Fionda, Lucia Florio, Melania Guida, Francesco Habetswallner, Raffaele Iorio, Pietro Luppino, Michelangelo Maestri Tassoni, Lorenzo Maggi, Martina Marini, Sofia Marini, Stefania Morino, Alessia Pugliese, Elena Rossini, Francesco Saccà, Alessio Sarnataro, Francesco Tuccillo, Fiammetta Vanoli, Massimiliano Ugo Verza, Claudia Vinciguerra, Rita Frangiamore Journal of the Neurological Sciences, 2025
Prevalence of hereditary transthyretin amyloidosis in CIDP patients with red flags: a multicenter genetic screening and misdiagnosis analysis Pietro Emiliano Doneddu, Giulia Moretti, Vincenzo Di Stefano, Yuri Falzone, Luca Leonardi, Marco Luigetti, Giorgia Mataluni, Luca Gentile, Marinella Carpo, Alessandro Barilaro, Massimiliano Filosto, Elisa Vegezzi, Maurizio Inghilleri, Fabrizio Canale, Filippo Brighina, Sabrina Matà, Adele Ratti, Francesca Forcina, Giovanni Siconolfi, Claudia Lozi, Anna Mazzeo, Ugo Mollo, Barbara Risi, Giuseppe Cosentino, Federica Moret, Carla Fasano, Vincenzo Todisco, Massimo Russo, Eduardo Nobile–Orazio Journal of Neurology, 2025
Analysis of the Italian cohort of late-onset Pompe disease (LOPD) patients after 10 and 15 years of therapy with alglucosidase alfa T. Mongini, G. Gadaleta, P. Alonge, L. Vercelli, I. Stura, O. Musumeci, S. Ravaglia, L. Ruggiero, A. Fiumara, R. Barone, S. Servidei, C. Sancricca, G. Siciliano, G. Ricci, A. Sechi, P. Tonin, E. Pegoraro, M. Filosto, G. D’Angelo, G. Comi, L. Maggi, A. Barp, G. Crescimanno, A. Toscano, , G. Migliaretti, F. Ricci, E. Rolle, M. Spada, G. Urbano, I. Arena, G. Falcone, M. Porcino, A. Pugliese, C. Rodolico, M. G. Croce, D. Zoppi, G. Primiano, C. Carlesi, E. Schirinzi, F. Torri, C. Dallatorre, L. Verriello, G. Vattemi, L. Bello, G. Capece, P. Riguzzi, F. Caria, L. Poli, B. Risi, E. Diella, S. Bonanno, M. Cheli, A. Gallone, E. Giacopuzzi, R. Tanel, A. Stano, R. Zuccarino, F. Brighina Journal of Neurology, 2025
Exploring semantic grounding in the posterior parietal cortex Umberto Quartetti, Chiara Finocchiaro, Giuditta Gambino, Filippo Brighina, Angelo Torrente, Fabrizio Di Giovanni, Danila Di Majo, Giuseppe Ferraro, Pierangelo Sardo, Giuseppe Giglia Brain Structure and Function, 2025
The Role of Non-Coding RNAs in ALS Alessandra Falduti, Adele Giovinazzo, Elisa Lo Feudo, Valentina Rocca, Filippo Brighina, Angela Messina, Francesca Luisa Conforti, Rodolfo Iuliano Genes, 2025
Evidence-based guidelines for the pharmacological treatment of migraine, summary version Raffaele Ornello, Valeria Caponnetto, Fayyaz Ahmed, Haidar M Al-Khazali, Anna Ambrosini, Sait Ashina, Carlo Baraldi, Alessia Bellotti, Filippo Brighina, Paolo Calabresi, Francesco Casillo, Sabina Cevoli, Shuli Cheng, Chia-Chun Chiang, Alberto Chiarugi, Rune Häckert Christensen, Min Kyung Chu, Gianluca Coppola, Ilenia Corbelli, Santiago Crema, Roberto De Icco, Marina De Tommaso, Cherubino Di Lorenzo, Vincenzo Di Stefano, Hans-Christoph Diener, Esme Ekizoglu, Adriana Fallacara, Valentina Favoni, Kimberly N Garces, Pierangelo Geppetti, Maria Teresa Goicochea, Antonio Granato, Franco Granella, Simona Guerzoni, Woo-Seok Ha, Amr Hassan, Koichi Hirata, Jan Hoffmann, Eva-Maria Hüssler, Mona Hussein, Luigi Francesco Iannone, Bronwyn Jenkins, Alejandro Labastida-Ramirez, Anna Laporta, Morris Levin, Antonino Lupica, Edoardo Mampreso, Daniele Martinelli, Teshamae S Monteith, Ilaria Orologio, Aynur Özge, Li-Ling Hope Pan, Lavindren Luke Panneerchelvam, Mario FP Peres, Marcio Nattan Portes Souza, Patricia Pozo-Rosich, Maria Pia Prudenzano, Silvia Quattrocchi, Innocenzo Rainero, Volodymyr Romanenko, Marina Romozzi, Antonio Russo, Grazia Sances, Paola Sarchielli, Todd J Schwedt, Marcello Silvestro, Diego Belardino Swerts, Cristina Tassorelli, Alessandro Tessitore, Mansoureh Togha, Gloria Vaghi, Shuu-Jiun Wang, Messoud Ashina, Simona Sacco Cephalalgia, 2025
Evidence-based guidelines for the pharmacological treatment of migraine Raffaele Ornello, Valeria Caponnetto, Fayyaz Ahmed, Haidar M. Al-Khazali, Anna Ambrosini, Sait Ashina, Carlo Baraldi, Alessia Bellotti, Filippo Brighina, Paolo Calabresi, Francesco Casillo, Sabina Cevoli, Shuli Cheng, Chia-Chun Chiang, Alberto Chiarugi, Rune Häckert Christensen, Min Kyung Chu, Gianluca Coppola, Ilenia Corbelli, Santiago Crema, Roberto De Icco, Marina de Tommaso, Cherubino Di Lorenzo, Vincenzo Di Stefano, Hans-Christoph Diener, Esme Ekizoğlu, Adriana Fallacara, Valentina Favoni, Kimberly N. Garces, Pierangelo Geppetti, Maria Teresa Goicochea, Antonio Granato, Franco Granella, Simona Guerzoni, Woo-Seok Ha, Amr Hassan, Koichi Hirata, Jan Hoffmann, Eva-Maria Hüssler, Mona Hussein, Luigi Francesco Iannone, Bronwyn Jenkins, Alejandro Labastida-Ramirez, Anna Laporta, Morris Levin, Antonino Lupica, Edoardo Mampreso, Daniele Martinelli, Teshamae S. Monteith, Ilaria Orologio, Aynur Özge, Li-Ling Hope Pan, Lavindren Luke Panneerchelvam, Mario F. P. Peres, Marcio Nattan Portes Souza, Patricia Pozo-Rosich, Maria Pia Prudenzano, Silvia Quattrocchi, Innocenzo Rainero, Volodymyr Romanenko, Marina Romozzi, Antonio Russo, Grazia Sances, Paola Sarchielli, Todd J. Schwedt, Marcello Silvestro, Diego Belandrino Swerts, Cristina Tassorelli, Alessandro Tessitore, Mansoureh Togha, Gloria Vaghi, Shuu-Jiun Wang, Messoud Ashina, Simona Sacco Cephalalgia an International Journal of Headache, 2025
Patisiran in ATTRv amyloidosis with polyneuropathy: “PatisiranItaly” multicenter observational study Vincenzo Di Stefano, Pietro Guaraldi, Angela Romano, Giovanni Antonini, Alessandro Barilaro, Chiara Briani, Marco Burattini, Ilaria Cani, Giulia Carlini, Marco Ceccanti, Vittoria Cianci, Pietro Cortelli, Marco Currò Dossi, Daniela Di Lisi, Antonio Di Muzio, Yuri Falzone, Massimiliano Filosto, Sabrina Gasverde, Chiara Gemelli, Luca Gentile, Mariangela Goglia, Luca Leonardi, Simone Longhi, Antonio Lotti, Fiore Manganelli, Anna Mazzeo, Giammarco Milella, Giuseppina Novo, Silvia Fenu, Giovanni Palumbo, Cristina Petrelli, Loris Poli, Luca Guglielmo Pradotto, Massimo Russo, Alessandro Salvalaggio, Maria Ausilia Sciarrone, Luigi Sellitti, Matteo Tagliapietra, Stefano Tozza, Mara Turri, Lorenzo Verriello, Francesca Vitali, Filippo Brighina, Marco Luigetti Journal of Neurology, 2025
Assessment of diagnostic criteria for multifocal motor neuropathy in patients included in the Italian database Pietro Emiliano Doneddu, Luca Gentile, Dario Cocito, Raffaella Fazio, Marco Luigetti, Chiara Briani, Massimiliano Filosto, Gabriele Siciliano, Luana Benedetti, Giovanni Antonini, Sabrina Matà, Girolama Alessandra Marfia, Maurizio Inghilleri, Fiore Manganelli, Giuseppe Cosentino, Filippo Brighina, Marinella Carpo, Francesca Carta, Anna Mazzeo, Erdita Peci, Camilla Strano, Angela Romano, Marta Campagnolo, Stefano Cotti‐Piccinelli, Divina Valeria Viola, Francesco Germano, Luca Leonardi, Martina Sperti, Giorgia Mataluni, Marco Ceccanti, Emanuele Spina, Elisa Vegezzi, Vincenzo Di Stefano, Eduardo Nobile‐Orazio European Journal of Neurology, 2024
Insomnia and Migraine: A Missed Call? Angelo Torrente, Lavinia Vassallo, Paolo Alonge, Laura Pilati, Andrea Gagliardo, Davide Ventimiglia, Antonino Lupica, Vincenzo Di Stefano, Cecilia Camarda, Filippo Brighina Clocks and Sleep, 2024
The Clinical Relevance of Artificial Intelligence in Migraine Angelo Torrente, Simona Maccora, Francesco Prinzi, Paolo Alonge, Laura Pilati, Antonino Lupica, Vincenzo Di Stefano, Cecilia Camarda, Salvatore Vitabile, Filippo Brighina Brain Sciences, 2024
Sex differences in neuromuscular disorders Claudia Vinciguerra, Salvatore Iacono, Liliana Bevilacqua, Annamaria Landolfi, Giuseppe Piscosquito, Federica Ginanneschi, Giuseppe Schirò, Vincenzo Di Stefano, Filippo Brighina, Paolo Barone, Carmela Rita Balistreri Mechanisms of Ageing and Development, 2023
New-onset headache following COVID-19: An Italian multicentre case series Angelo Torrente, Paolo Alonge, Vincenzo Di Stefano, Roberta Baschi, Raffaele Ornello, Edvige Correnti, Antonino Lupica, Cecilia Camarda, Gabriella Farinella, Vincenzo Raieli, Simona Sacco, Roberto Monastero, Filippo Brighina Journal of the Neurological Sciences, 2023
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey Giorgia Coratti, Martina Ricci, Anna Capasso, Adele D'amico, Valeria Sansone, Claudio Bruno, Sonia Messina, Federica Ricci, Tiziana Mongini, Michela Coccia, Gabriele Siciliano, Elena Pegoraro, Mara Turri, Massimiliano Filosto, Giacomo Comi, Riccardo Masson, Lorenzo Maggi, Irene Bruno, Maria Grazia D'Angelo, Antonio Trabacca, Veria Vacchiano, Maria Donati, Isabella Simone, Lucia Ruggiero, Antonio Varone, Lorenzo Verriello, Angela Berardinelli, Caterina Agosto, Antonella Pini, Maria Antonietta Maioli, Luigia Passamano, Filippo Brighina, Nicola Carboni, Matteo Garibaldi, Riccardo Zuccarino, Delio Gagliardi, Sabrina Siliquini, Stefano Previtali, Domenica Taruscio, Stefania Boccia, Maria Carmela Pera, Marika Pane, Eugenio Mercuri, and Neurology, 2023
Sleep and Chronobiology as a Key to Understand Cluster Headache Laura Pilati, Angelo Torrente, Paolo Alonge, Lavinia Vassallo, Simona Maccora, Andrea Gagliardo, Antonia Pignolo, Salvatore Iacono, Salvatore Ferlisi, Vincenzo Di Stefano, Cecilia Camarda, Filippo Brighina Neurology International, 2023
Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis Davide Norata, Marta Peri, Giuseppe Roberto Giammalva, Antonino Lupica, Federica Paolini, Lorena Incorvaia, Giuseppe Badalamenti, Valerio Gristina, Antonio Galvano, Antonio Russo, Domenico Gerardo Iacopino, Mauro Silvestrini, Viviana Bazan, Filippo Brighina, Vincenzo Di Stefano Diagnostics, 2023
Digitalized transcranial electrical stimulation: A consensus statement Andre R Brunoni, Hamed Ekhtiari, Andrea Antal, Paradee Auvichayapat, Chris Baeken, Isabela M. Benseñor, Marom Bikson, Paulo Boggio, Barbara Borroni, Filippo Brighina, Jerome Brunelin, Sandra Carvalho, Wolnei Caumo, Patrick Ciechanski, Leigh Charvet, Vincent P. Clark, Roi Cohen Kadosh, Maria Cotelli, Abhishek Datta, Zhi-De Deng, Rudi De Raedt, Dirk De Ridder, Paul B. Fitzgerald, Agnes Floel, Flavio Frohlich, Mark S. George, Peyman Ghobadi-Azbari, Stephan Goerigk, Roy H. Hamilton, Shapour J. Jaberzadeh, Kate Hoy, Dawson J. Kidgell, Arash Khojasteh Zonoozi, Adam Kirton, Steven Laureys, Michal Lavidor, Kiwon Lee, Jorge Leite, Sarah H. Lisanby, Colleen Loo, Donel M. Martin, Carlo Miniussi, Marine Mondino, Katia Monte-Silva, Leon Morales-Quezada, Michael A. Nitsche, Alexandre H. Okano, Claudia S. Oliveira, Balder Onarheim, Kevin Pacheco-Barrios, Frank Padberg, Ester M. Nakamura-Palacios, Ulrich Palm, Walter Paulus, Christian Plewnia, Alberto Priori, Tarek K. Rajji, Lais B. Razza, Erik M. Rehn, Giulio Ruffini, Klaus Schellhorn, Mehran Zare-Bidoky, Marcel Simis, Pawel Skorupinski, Paulo Suen, Aurore Thibaut, Leandro C.L. Valiengo, Marie-Anne Vanderhasselt, Sven Vanneste, Ganesan Venkatasubramanian, Ines R. Violante, Anna Wexler, Adam J. Woods, Felipe Fregni Clinical Neurophysiology, 2022
Adherence and Reactogenicity to Vaccines against SARS-COV-2 in 285 Patients with Neuropathy: A Multicentric Study Salvatore Iacono, Vincenzo Di Stefano, Paolo Alonge, Claudia Vinciguerra, Giammarco Milella, Francesca Caputo, Piergiorgio Lasorella, Gabriele Neto, Antonia Pignolo, Angelo Torrente, Antonino Lupica, Paola Ajdinaj, Alberto Firenze, Stefano Tozza, Fiore Manganelli, Antonio Di Muzio, Giuseppe Piscosquito, Filippo Brighina Brain Sciences, 2022
The role of serum free light chain as biomarker of Myasthenia Gravis Caterina Maria Gambino, Luisa Agnello, Bruna Lo Sasso, Rosaria Vincenza Giglio, Vincenzo Di Stefano, Giuseppina Candore, Emanuela Maria Pappalardo, Anna Maria Ciaccio, Filippo Brighina, Matteo Vidali, Marcello Ciaccio Clinica Chimica Acta, 2022
Migraine and handedness Giovanni Battista La Pegna, Giuseppe Quatrosi, Luigi Vetri, Federica Reina, Cristina Galati, Maria Laura Manzo, Giovanna Martina Nocera, Filippo Brighina, Vincenzo Raieli Neurological Sciences, 2021
Social distancing in chronic migraine during the covid-19 outbreak: Results from a multicenter observational study Vincenzo Di Stefano, Raffaele Ornello, Andrea Gagliardo, Angelo Torrente, Elisa Illuminato, Valeria Caponnetto, Ilaria Frattale, Raffaella Golini, Chiara Di Felice, Fabiola Graziano, Maria Caccamo, Davide Ventimiglia, Salvatore Iacono, Gabriella Matarazzo, Francesco Armetta, Giuseppe Battaglia, Alberto Firenze, Simona Sacco, Filippo Brighina Nutrients, 2021
Erratum: T helper 1 response is correlated with widespread pain, fatigue, sleeping disorders and the quality of life in patients with fibromyalgia and is modulated by hyperbaric oxygen therapy (Clinical and experimental rheumatology (2019) 37 Suppl 116 1 (81-89)) Clinical and Experimental Rheumatology, 2020
Migraine as a Cortical Brain Disorder Piero Barbanti, Filippo Brighina, Gabriella Egeo, Vincenzo Di Stefano, Marcello Silvestro, Antonio Russo Headache, 2020
Diagnostic and therapeutic aspects of hemiplegic migraine Vincenzo Di Stefano, Marianna Gabriella Rispoli, Noemi Pellegrino, Alessandro Graziosi, Eleonora Rotondo, Christian Napoli, Daniela Pietrobon, Filippo Brighina, Pasquale Parisi Journal of Neurology Neurosurgery and Psychiatry, 2020
Migraine in children under 6 years of age: A long-term follow-up study Francesca Marchese, Luciana Rocchitelli, Luca Maria Messina, Rosaria Nardello, Giuseppe Donato Mangano, Francesca Vanadia, Salvatore Mangano, Filippo Brighina, Vincenzo Raieli European Journal of Paediatric Neurology, 2020
Poor patient awareness and frequent misdiagnosis of migraine: findings from a large transcontinental cohort M. Viana, F. Khaliq, C. Zecca, M. D. L. Figuerola, G. Sances, V. Di Piero, B. Petolicchio, M. Alessiani, P. Geppetti, C. Lupi, S. Benemei, R. Iannacchero, F. Maggioni, M. E. Jurno, S. Odobescu, E. Chiriac, A. Marfil, F. Brighina, N. Barrientos Uribe, C. Pérez Lago, C. Bordini, F. Lucchese, V. Maffey, G. Nappi, G. Sandrini, C. Tassorelli European Journal of Neurology, 2020
T helper 1 response is correlated with widespread pain, fatigue, sleeping disorders and the quality of life in patients with fibromyalgia and is modulated by hyperbaric oxygen therapy Clinical and Experimental Rheumatology, 2019
Motor cortex tRNS improves pain, affective and cognitive impairment in patients with fibromyalgia: Preliminary results of a randomised sham-controlled trial Clinical and Experimental Rheumatology, 2017
Comments Albert Leung, Shivshil Shukla, Amir Fallah, David Song, Lisa Lin, Shahrokh Golshan, Alice Tsai, Amy Jak, Greg Polston, Roland Lee Neuromodulation, 2016
Altered processing of sensory stimuli in patients with migraine Marina de Tommaso, Anna Ambrosini, Filippo Brighina, Gianluca Coppola, Armando Perrotta, Francesco Pierelli, Giorgio Sandrini, Massimiliano Valeriani, Daniele Marinazzo, Sebastiano Stramaglia, Jean Schoenen Nature Reviews Neurology, 2014
Efficacy and safety of topiramate in migraine prophylaxis: An open controlled randomized study comparing Sincronil and Topamax formulations Panminerva Medica, 2013
Brain stimulation in migraine Filippo Brighina, Giuseppe Cosentino, Brigida Fierro Handbook of Clinical Neurology, 2013
Sound-induced flash illusions as a paradigm of multisensorial integration: A review article Acta Medica Mediterranea, 2013
Neuromodulation of chronic headaches: Position statement from the European Headache Federation Paolo Martelletti, Rigmor H Jensen, Andrea Antal, Roberto Arcioni, Filippo Brighina, Marina de Tommaso, Angelo Franzini, Denys Fontaine, Max Heiland, Tim P Jürgens, Massimo Leone, Delphine Magis, Koen Paemeleire, Stefano Palmisani, Walter Paulus, Arne May Journal of Headache and Pain, 2013
Two cases of non-alcoholic Wernicke encephalopathy successfully treated by thiamine replacement: Diagnostic and therapeutic considerations Acta Medica Mediterranea, 2010
A validation study of an Italian version of the "ID Migraine" Filippo Brighina, Giuseppe Salemi, Brigida Fierro, Antonio Gasparro, Antonio Balletta, Antonina Aloisio, Giovanni La Pegna, Giovanna Randisi, Vincenzo Saporito, Giuseppe Calagna, Filippo La Naia, Rossana Morana Headache, 2007
Erratum: Timing of right parietal and frontal cortex activity in visuo-spatial perception: A TMS study of normal individuals (NeuroReport (March 2001) 12 (2605-2607)) Neuroreport, 2002
Slow-frequency repetitive transcranial magnetic stimulation in patients with cortical dysplasia: Preliminary results Bollettino Lega Italiana Contro L Epilessia, 2001
Comorbidity of headache and epilepsy: Preliminary results Bollettino Lega Italiana Contro L Epilessia, 2001